乙肝“临床治愈”国家攻关推进 广生堂在研创新药入列

Core Viewpoint - The announcement by Guangshengtang regarding its innovative hepatitis B drugs aligns with national policies aimed at achieving "clinical cure" for hepatitis B, receiving substantial support from the government [1][2]. Group 1: Project Overview - Guangshengtang's subsidiary, Fujian Guangsheng Zhonglin Biotechnology Co., has been included in a national major science and technology project focused on the clinical cure of chronic hepatitis B [1][2]. - The project, led by Southern Medical University, aims to explore and establish a clinically applicable hepatitis B cure and improve cure rates by 2028 [2]. Group 2: Market Demand and Public Health Significance - As of 2022, there are approximately 79.74 million HBV infected individuals in China, with chronic hepatitis B patients numbering between 20 to 30 million, highlighting a significant unmet clinical need [3]. - The national action plan for hepatitis virus prevention and control sets ambitious targets for diagnosis and treatment rates by 2030, emphasizing the urgency for innovative treatment solutions [3]. Group 3: Drug Development and Clinical Trials - The two innovative drugs, GST-HG131 and GST-HG141, are central to Guangshengtang's strategy and have shown strong competitive potential internationally [4][5]. - GST-HG131 is the first oral hepatitis B surface antigen inhibitor to complete Phase II clinical trials, demonstrating significant reductions in HBsAg levels [4]. - GST-HG141, a novel core protein regulator, has shown promising results in reducing HBV pgRNA levels, indicating potential for addressing the challenges of treatment discontinuation [5]. Group 4: Strategic Implications for Guangshengtang - Participation in the national project will provide Guangshengtang with expert guidance and collaboration opportunities, reinforcing its leading position in hepatitis B treatment [6]. - Successful outcomes from the project could influence industry standards and contribute to the development of clinical guidelines for chronic hepatitis B treatment in China [6].